BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20192118)

  • 21. Garcinol, a polyisoprenylated benzophenone modulates multiple proinflammatory signaling cascades leading to the suppression of growth and survival of head and neck carcinoma.
    Li F; Shanmugam MK; Chen L; Chatterjee S; Basha J; Kumar AP; Kundu TK; Sethi G
    Cancer Prev Res (Phila); 2013 Aug; 6(8):843-54. PubMed ID: 23803415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog.
    Abuzeid WM; Davis S; Tang AL; Saunders L; Brenner JC; Lin J; Fuchs JR; Light E; Bradford CR; Prince ME; Carey TE
    Arch Otolaryngol Head Neck Surg; 2011 May; 137(5):499-507. PubMed ID: 21576562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction.
    Masuda M; Suzui M; Lim JT; Deguchi A; Soh JW; Weinstein IB
    J Exp Ther Oncol; 2002; 2(6):350-9. PubMed ID: 12440226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
    Bu LL; Zhao ZL; Liu JF; Ma SR; Huang CF; Liu B; Zhang WF; Sun ZJ
    Oncotarget; 2015 Dec; 6(39):41944-58. PubMed ID: 26556875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Theraputic targeting of Trk supresses tumor proliferation and enhances cisplatin activity in HNSCC.
    Yilmaz T; Jiffar T; de la Garza G; Lin H; Milas Z; Takahashi Y; Hanna E; MacIntyre T; Brown JL; Myers JN; Kupferman ME
    Cancer Biol Ther; 2010 Sep; 10(6):644-53. PubMed ID: 20703101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
    Tang YJ; Sun ZL; Wu WG; Xing J; He YF; Xin DM; Han P
    Genet Mol Res; 2015 Mar; 14(1):2450-60. PubMed ID: 25867391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Study of Kinase Inhibitor WP1066 on the STAT3/JAK2 of Prostate Stromal Cells].
    Li YX; Li JM; Wei Q; Zhang ZP; Wu J; Wang AG
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 49(1):65-68. PubMed ID: 29737092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo.
    Iwamaru A; Szymanski S; Iwado E; Aoki H; Yokoyama T; Fokt I; Hess K; Conrad C; Madden T; Sawaya R; Kondo S; Priebe W; Kondo Y
    Oncogene; 2007 Apr; 26(17):2435-44. PubMed ID: 17043651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells.
    Lu K; Chen N; Zhou XX; Ge XL; Feng LL; Li PP; Li XY; Geng LY; Wang X
    Biochem Biophys Res Commun; 2015 Aug; 464(1):292-8. PubMed ID: 26116769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding.
    Sen B; Saigal B; Parikh N; Gallick G; Johnson FM
    Cancer Res; 2009 Mar; 69(5):1958-65. PubMed ID: 19223541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
    Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR
    Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR-204 inhibits angiogenesis and promotes sensitivity to cetuximab in head and neck squamous cell carcinoma cells by blocking JAK2-STAT3 signaling.
    Wu Q; Zhao Y; Wang P
    Biomed Pharmacother; 2018 Mar; 99():278-285. PubMed ID: 29353201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
    Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
    Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma.
    Bharadwaj U; Eckols TK; Xu X; Kasembeli MM; Chen Y; Adachi M; Song Y; Mo Q; Lai SY; Tweardy DJ
    Oncotarget; 2016 May; 7(18):26307-30. PubMed ID: 27027445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guggulsterone (GS) inhibits smokeless tobacco and nicotine-induced NF-κB and STAT3 pathways in head and neck cancer cells.
    Macha MA; Matta A; Chauhan SS; Siu KW; Ralhan R
    Carcinogenesis; 2011 Mar; 32(3):368-80. PubMed ID: 21177768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
    Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
    Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.
    Boehm AL; Sen M; Seethala R; Gooding WE; Freilino M; Wong SM; Wang S; Johnson DE; Grandis JR
    Mol Pharmacol; 2008 Jun; 73(6):1632-42. PubMed ID: 18326051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy.
    Assi HH; Paran C; VanderVeen N; Savakus J; Doherty R; Petruzzella E; Hoeschele JD; Appelman H; Raptis L; Mikkelsen T; Lowenstein PR; Castro MG
    J Pharmacol Exp Ther; 2014 Jun; 349(3):458-69. PubMed ID: 24696041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma.
    Oh SH; Kim WY; Kim JH; Younes MN; El-Naggar AK; Myers JN; Kies M; Cohen P; Khuri F; Hong WK; Lee HY
    Clin Cancer Res; 2006 Jan; 12(2):653-61. PubMed ID: 16428512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.